Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

Abstract

Background: Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events. Methods: A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane. Results: Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1–3 adverse events, 15 (57.7%) experienced 4–6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events. Conclusion: Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.